Catalyst Pharmaceuticals closes $150M public offering of 10M shares at $15; net proceeds ~$140.1M

CATALYST PHARMACEUTICALS, INC.

Sold 10,000,000 shares of common stock at $15.00 per share in an underwritten public offering.
Net proceeds after underwriting discounts and estimated expenses were approximately $140.1 million.
Underwriters granted a 30-day option to purchase up to an additional 1,500,000 shares.
Proceeds to be used for potential acquisition of new product candidates and general corporate purposes.
Bookrunners: BofA Securities, Citigroup, Piper Sandler, Cantor, Truist Securities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.